During the past decade, Shanghai Skin Disease Hospital conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 1 clinical trials were completed, i.e. on average, 4.8% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 1 clinical trials were completed. i.e. 5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai Skin Disease Hospital" #1 sponsor was "Reistone Biopharma Company Limited" with 5 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Keymed Biosciences Co.Ltd" with 2 trials sponsored and "Staidson (Beijing) Biopharmaceuticals Co., Ltd" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai Skin Disease Hospital" #1 collaborator was "Shanghai China-Norm Management Consulting co.,LTD" with 1 trials as a collaborator, "Shanghai Skin Disease Hospital" with 1 trials as a collaborator and "Shanghai Skin Disease and Venereal Disease Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai Skin Disease Hospital" are "Generalized Pustular Psoriasis" (4 trials), "Alopecia Areata" (2 trials), "Atopic Dermatitis" (2 trials), "Hidradenitis Suppurativa" (2 trials) and "Moderate-to-severe Atopic Dermatitis" (2 trials). Many other conditions were trialed in "Shanghai Skin Disease Hospital" in a lesser frequency.

Most popular intervention types in "Shanghai Skin Disease Hospital" are "Drug" (17 trials), "Other" (3 trials), "Biological" (2 trials), "Combination Product" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Spesolimab" (3 trials), "BDB-001 Injection" (2 trials), "CM310" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai Skin Disease Hospital" are 19 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Shanghai Skin Disease Hospital". 1 are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Shanghai Skin Disease Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai Skin Disease Hospital, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".